0000885590-13-000016.txt : 20130306 0000885590-13-000016.hdr.sgml : 20130306 20130306191412 ACCESSION NUMBER: 0000885590-13-000016 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130128 FILED AS OF DATE: 20130306 DATE AS OF CHANGE: 20130306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Weldon Ryan CENTRAL INDEX KEY: 0001564233 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 13671145 MAIL ADDRESS: STREET 1: 4787 LEVY STREET CITY: MONTREAL STATE: A8 ZIP: H4R 2P9 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4787 LEVY STREET STREET 2: MONTREAL CITY: QUEBEC STATE: A8 ZIP: H4R 2P9 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 4787 LEVY STREET STREET 2: MONTREAL CITY: QUEBEC STATE: A8 ZIP: H4R 2P9 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2013-01-28 0 0000885590 Valeant Pharmaceuticals International, Inc. VRX 0001564233 Weldon Ryan 4787 LEVY STREET MONTREAL A8 H4R 2P9 QUEBEC, CANADA 0 1 0 0 EVP, Company Group Chairman Non-Qualified Stock (rights to purchase) 69.41 2013-03-05 4 A 0 13700 0 A 2017-03-05 2023-03-05 Common Shares, no par value 13700 13700 D Restricted Share Units 0 2013-01-28 4 A 0 11000 0 A Common Shares, no par value 11000 11000 D The options vest 25% per year for 4 years starting from the date of grant with the first vest date falling on the first anniversary of the grant, the second vest date falling on the second anniversary of the grant, the third vest date falling on the third anniversary of the grant and the fourth vest date falling on the fourth anniversary of the grant. Each Restricted Share Unit ("RSUs") represents a contingent right to receive between zero and three common shares, no par value, of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (3). The performance based RSUs are eligible to vest on the achievement of TSR targets ranging from 10% to 30% over a base price of $62.62 on each of three measurement dates: 25% would vest on October 28, 2015, 50% on January 28, 2016 and 25% on April 28, 2016, with early vesting possible at higher TSR levels. by: Nicholas Zanoni for Ryan Weldon 2013-03-06